Anti-reflux medication use in preterm infants by Binti Abdul Hamid, Haslina et al.
CLINICAL RESEARCH ARTICLE OPEN
Anti-reflux medication use in preterm infants
Haslina Binti Abdul Hamid1,2, Lisa Szatkowski1, Helen Budge1 and Shalini Ojha1,3✉
© The Author(s) 2021
BACKGROUND: Current recommendations do not support the use of anti-reflux medications to treat gastro-oesophageal reflux
disease (GORD) among preterm infants.
OBJECTIVE: To describe the prevalence of GORD and the use of anti-reflux medications amongst very preterm infants (<32 weeks’
gestational age (GA)) in neonatal units in England and Wales.
DESIGN: Retrospective cohort study using the National Neonatal Research Database.
RESULTS: Among 58,108 infants [median GA (IQR) 29 (27–30) weeks], 15.8% (n= 9191) had a diagnosis of GORD and 36.9%
(n= 12,446) received anti-reflux medications. Those who received anti-reflux medications were more preterm [GA, median (IQR):
medications, 28 (26–30) vs. no medications, 30 (28–31); p < 0.001] and had lower birth weight [mean (SD): medications, 1124 g (354)
vs. no medications, 1265 g (384); p < 0.001]. Most (57%, n= 12,224) received Gaviscon, or Histamine-2 Receptor Antagonist (H2RA)
(56%, n= 11,959). Over time, prokinetic use has declined substantially, the use of H2RAs and Gaviscon has reduced although they
continue to be used frequently, whilst the use of PPIs has increased.
CONCLUSIONS: Anti-reflux medications are frequently prescribed in very preterm infants, despite evidence to suggest that they are
not effective and may be harmful. Clear guidelines for diagnosing GORD and the use of anti-reflux medications are required to
rationalise the pharmacological management of GORD in preterm infants.
Pediatric Research; https://doi.org/10.1038/s41390-021-01821-y
IMPACT:
● Anti-reflux medications are frequently prescribed, often without a diagnosis of gastro-oesophageal reflux disease, to very
preterm infants while in the neonatal unit and at discharge.
● Half of the infants born at <28 weeks’ gestational age receive anti-reflux medications in hospital and a quarter are discharged
home on them.
● Although the use of prokinetics declined following alerts of adverse events, histamine2-receptor antagonists and alginates such
as Gaviscon continue to be used and the use of proton-pump inhibitors has increased more than 2-fold.
INTRODUCTION
Gastro-oesophageal reflux (GOR), the passage of gastric contents
into the oesophagus, is common in preterm infants.1 It usually
occurs due to the relatively abundant volume of liquid intake and
supine feeding position. However, GOR can worsen and lead to
troublesome signs and symptoms i.e., gastro-oesophageal reflux
disease (GORD).
Determination of the exact prevalence of GOR versus GORD is
challenging because of an unclear distinction between physiolo-
gic and pathologic reflux. Additionally, the terms “reflux”, “acid-
reflux”, and GORD are often used interchangeably by healthcare
professionals as well parents and families of infants.2 In a
retrospective cohort study of 33 neonatal units in the USA,3 there
was a wide variation between the units in the proportion of
preterm infants who received a diagnosis of GORD based on the
International Classification of Diseases (ICD-9). Approximately 10%
of infants born at 22−36 weeks gestational age (GA) were
recorded to have GORD with diagnosis prevalence ranging from
2.4 to 29.9% across the included neonatal units.
Anti-reflux medications, including Histamine-2 receptor antago-
nists (H2RA) and proton-pump inhibitors (PPI), are unlicensed for
use in neonates in the UK and many other countries,4 though off-
label use is frequently reported.5 Antacids and other acid-
suppressing agents may reduce gastric acidity but anti-reflux
medications do not improve signs/symptoms of GORD and their
use has been associated with increased risks of adverse outcomes
including necrotising enterocolitis (NEC) and infections.6 The
North American Society for Pediatric Gastroenterology, Hepatol-
ogy, and Nutrition and European Society for Paediatric Gastro-
enterology Hepatology and Nutrition (NASPGHAN and ESPGHAN
combined) clinical practice guidelines1 suggests non-
pharmacological approaches to GORD before pharmacological
therapy. Similarly, the American Academy of Paediatrics recom-
mends that anti-reflux medications should be used with caution, if
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at all, in preterm infants due to lack of evidence of efficacy and
possible significant harm.7
Despite these recommendations, anti-reflux medications are
frequently used. A large retrospective study including infants
admitted to neonatal units in 43 children’s hospitals in the USA
reported that 24% received either an H2RA or PPI with the
extremely preterm infants being the most likely to receive these
medicines.8 Similarly, Malcolm et al.9 reported that a quarter of
extremely low birth weight infants who were enrolled in the
National Institute of Child Health and Human Development
Neonatal Network generic database in 2002–2003 were dis-
charged from the hospital with anti-reflux medications.
In the UK, two survey studies of neonatal healthcare profes-
sionals, in 200410 and 2018,11 revealed that clinicians reported
frequently prescribing anti-reflux medications in neonatal units.
Dhillon and Ewer10 reported that, in 2004, nearly all respondents
used anti-reflux medications to manage GOR. In 2018, another
survey showed that the use of anti-reflux medications remained
popular11 despite the increasing evidence of lack of efficacy and
possible harm. Both studies analysed the use of medications as
reported by clinicians. There are no studies that have analysed the
prevalence of GORD diagnosis and the actual use of anti-reflux
medications in neonatal units in the UK.
In this study, we aimed to describe the prevalence of GORD
diagnosis and use of anti-reflux medications amongst very
preterm infants in England and Wales. We also aimed to analyse
the types of medications used, duration and trend of medications
use between 2010 and 2017.
METHODS
We conducted a retrospective observational cohort study using the data
held in the National Neonatal Research Database (NNRD). The NNRD is a
repository of clinical data of admissions to the 200 neonatal units in
England, Wales and Scotland that make up the UK Neonatal Collaborative.12
Identification of study cohort
Infants born <32 weeks’ gestational age (GA), in England and Wales from
2010 until 2017, whose data are held in the NNRD were included. Infants
were excluded if they were missing data on sex, birth weight, month of
birth or one or more days of care, were a late admission to neonatal care
(>24 h) or had an extreme birth weight for GA (Z-score ≥+4 SD or ≤−4SD).
Data extraction
Records of GORD were extracted by searching for specified terms in the
“principal diagnosis at admission”, “daily diagnoses” and “diagnoses at
discharge” fields. A list of anti-reflux medications for GORD was prepared
according to the British National Formulary (BNF) and included Ranitidine
(H2RA), Omeprazole and Lansoprazole (PPI), Domperidone, Metoclopra-
mide, and Erythromycin (Prokinetics). Indicator variables were created for
each day of care to show whether an infant was prescribed any of the anti-
reflux medications. Code lists are available from the authors on request.
Data analysis
Statistical analysis was performed using STATA 16.0 software (Stata Corp.
College Station, TX). Descriptive statistics were used to describe infant
characteristics, the prevalence of GORD and the use of anti-reflux
medications. Values are presented as numbers and percentages for
categorical data and for continuous variables, mean [±standard deviation
(SD)] used for normally distributed data and median [interquartile range
(IQR)] for non-normally distributed data. Linear regression was used where
appropriate to quantify trends over time in medication use.
RESULTS
Among the total of 58,108 infants, 69.9% (n= 40,607) were born at
28–31 weeks GA and 30.1% (n= 17,501) were born at <28 weeks
GA. 45.8% (n= 26,596) were female. Median (IQR) GA was
29 weeks (27–30), and the mean (SD) birth weight was 1213 g
(379). The median (IQR) length of hospital stay was 49 days
(34–74) and median (IQR) postmenstrual age (PMA) at discharge
was 36 weeks (35–38).
Table 1 shows that 15.8% (n= 9191) of total infants had any
record of GORD. Infants first received GORD diagnosis at median
(IQR) PMA of 36 (33–38) weeks. Infants with a diagnosis of GORD
were more preterm than infants without a diagnosis [GA, median
(IQR): GORD, 28 weeks (26–30) vs. no GORD, 29 weeks (27–31);
p < 0.001], had lower birth weight [mean (SD): GORD, 1114 g (337)
vs. no GORD, 1232 g (384); p < 0.001] and fewer were female [n
(%): GORD, 3856 (42.0%) vs. no GORD, 22,740 (46.5%); p < 0.001].
Of all the infants, 36.9% (n= 21,446) received anti-reflux
medications during admission and 18.2% were receiving them
at discharge (Table 1). However, among those who received anti-
reflux medications, only 39.6% had a diagnosis of GORD. The PMA
[median (IQR)] at first prescription of an anti-reflux medication was
32 weeks (30–34) and the treatments were continued for a median
(IQR) duration of 20 days (9–37). 49.3% (n= 8634/17,501) of
extremely preterm infants received anti-reflux medications during
admission and 24.9% (n= 4352/17,501) were receiving them at
discharge. Infants who received anti-reflux medications were more
preterm [GA, median (IQR): medications, 28 (26–30) vs. no
medications, 30 (28–31); p < 0.001], had lower birth weight [mean
(SD): medications, 1124 g (354) vs. no medications, 1265 g (384);
p < 0.001] and fewer were female [n (%): medications, 9172
(42.8%) vs. no medications, 17,424 (47.5%); p < 0.001].
Table 2 shows that among all infants who received anti-reflux
medications (36.9%, n= 21,466), the largest number had Gaviscon
(57%, n= 12,224) followed by H2RA (55.8%, n= 11,959), proki-
netics (45.4%, n= 9734) and PPI (16.2%, n= 3480). The use of
these medications among the subgroups of <28 weeks’ and
28–32 weeks’ GA is given in Table 2. Extremely preterm infants
received all types of medications more frequently and for longer.
During their stay, 11.4% (n= 6624) infants received two and
6.4% (n= 3687) received three types of anti-reflux medications.
16.7% (n= 9694) of infants received two or more anti-reflux
Table 1. Diagnosis of gastro-oesophageal reflux disease (GORD) and use of anti-reflux medications in infants born at <32 weeks’ gestational age in







Any record of GORD diagnosis, n (%) 9191 (15.8) 3951 (22.6) 5240 (12.9)
PMA (weeks) at first GORD diagnosis, median (IQR) 36 (33–38) 36 (32–39) 35 (33–37)
Received anti-reflux medications in hospital, n (%) 21,446 (36.9) 8634 (49.3) 12,812 (31.6)
PMA (weeks) at first anti-reflux prescription, median (IQR) 32 (30–34) 30 (28–34) 32 (31–34)
Number of days of anti-reflux medications, median (IQR) 20 (9–37) 27 (11–49) 18 (9–30)
Receiving anti-reflux medications at discharge, n (%) 10,558 (18.2) 4352 (24.9) 6206 (15.3)
GORD gastro-oesophageal disease, PMA postmenstrual age, IQR interquartile range.
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medications on the same day of care and 8.6% (n= 4986) of
infants were on two or more anti-reflux medications at discharge.
The change in prescribing of anti-reflux medications between
2010 and 2017 is shown in Fig. 1. The use of prokinetics sharply
declined after 2013 (from 23.7% in 2013 to 6.9% in 2017). There
was a smaller reduction in the use of H2RAs after 2013 (from
23.7% in 2013 to 17.9% in 2017). There was a linearly decreasing
trend in the use of Gaviscon over the time period (from 20.7% in
2013 to 19.7% in 2017, β=−0.44, 95% CI −0.55 to −0.32, p <
0.001)). The proportion of infants prescribed with PPI increased
more than twofold (4.2% in 2010 to 8.9% in 2017, β= 0.60, 95% CI
0.40 to 0.79, p < 0.001).
DISCUSSION
Anti-reflux medications were prescribed to 37% of infants born at
<32 weeks’ GA in England and Wales and over 18% were
discharged home on these medicines. We found that, on average,
anti-reflux medications are started at 32 weeks’ PMA and given for
3 weeks. Our findings show that anti-reflux medication use is more
prevalent amongst extremely premature infants. Half of the
infants born at <28 weeks’ GA received anti-reflux medication in
hospital and a quarter at discharge. This group also received anti-
reflux medications for, on average, 9 days more compared to the
infants born at 28–31 weeks’ GA.
A wide range of clinical signs/symptoms amongst preterm
infants are linked to GORD but none are pathognomonic making
it difficult to diagnose clinically. In this database, a diagnosis of
GORD was reported in 16% of infants born at <32 weeks’ GA.
Previous estimates from UK survey data10 report a higher
prevalence at 22% in infants born at <34 weeks’ GA. Such
surveys, however, report the incidence as estimated by the
responding clinician and therefore may not represent true
prevalence. We found a lower prevalence reported in the NNRD
among <32 weeks’ GA infants while Jadcherla et al.3, in a study
from 33 hospitals in the United States, reported that 10% of all
preterm infants (≤37 weeks GA) had a diagnosis of GORD. The
information available in the NNRD does not include how the
diagnosis was made and whether any investigations or diagnostic
tools were used to determine the presence and severity of GORD.
Investigations such as pH monitoring, multichannel intra-
oesophageal impedance monitoring, contrast fluoroscopy, endo-
scopy and biopsy are infrequently used for diagnosis in UK
neonatal practice and most cases, are diagnosed based on clinical
features or clinical features and a therapeutic trial with anti-reflux
medications.10,11 Although pH monitoring is available in most
neonatal units, less than a third report using it10 possibly because
it may not be a reliable marker of GORD in preterm infants. The
stomach pH of preterm infants is rarely <4 due to frequent milk
feeding and a higher baseline pH.7 Moreover, higher acidity in the
Table 2. Types of anti-reflux medication and number of days prescribed in infants born at <32 weeks’ gestational age in England and Wales from
2010 to 2017.
Received anti-reflux medications






Gaviscon, n (%) 12,224 (57.0) 4467 (51.7) 7757 (60.5)
Number of days, median (IQR) 17 (8–29) 21 (10–37) 15 (8–25)
PPI, n (%) 3480 (16.2) 1736 (20.1) 1744 (13.6)
Number of days, median (IQR) 20 (10–34) 24 (11–41) 18 (9–29)
H2RA, n (%) 11,959 (55.8) 5533 (64.1) 6426 (50.2)
Number of days, median (IQR) 15 (6–30) 17 (7–35) 14 (6–26)
Prokinetics, n (%) 9734 (45.4) 4231 (49.0) 5503 (43.0)
Number of days, median (IQR) 21 (10–37) 27 (12–48) 19 (9–31)



























Fig. 1 Trends in prescribing anti-reflux medications among infants born at <32 weeks’ gestational age in England and Wales from 2010
to 2017. H2RA histamine-2 receptor antagonists, PPI proton-pump inhibitors.
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oesophagus does not correlate with symptoms of GORD in
newborn infants.13
Most infants had GORD diagnosis later in the course of their
neonatal stay. The median (IQR) of PMA at first GORD diagnosis
was 36 weeks (33–38). Difficulties with feeding such as vomiting,
regurgitation or discomfort after large volume feeds often
manifest only after the establishment of higher feed volumes.
Airways are often protected with devices such as endotracheal
tubes and breathing supported with additional respiratory
support in the early days after birth. Cardio-respiratory events
such as episodes of desaturations may manifest later. These signs
may be taken to be suggestive of GOR and may prompt trials of
treatment and diagnosis of GORD.
When comparing infants who had a recorded diagnosis of
GORD with those who did not, we found that those with GORD
diagnosis were more premature and lighter at birth. This is
consistent with studies showing that the occurrence of GOR and
GORD were higher in younger preterm infants as compared to
more matured preterm infants, as well as in lower birth weight
infants.3 This could be because mechanisms of GORD such as
transient lower oesophageal sphincter relaxation (TLESR) are more
frequent in more premature infants.13 TLESR can lower oesopha-
geal sphincter pressure to levels at, or below, intragastric pressure
causing regurgitation of stomach contents. In terms of physiolo-
gical or structural maturity, less mature infants have lower
oesophageal peristaltic velocity as well as a shorter oesophagus
and lower oesophageal sphincter (LES) which would exacerbate
GOR events more than in more mature infants.7 Other factors
related to preterm infants’ risk of GORD are relatively abundant
milk intake, body position and cow’s milk protein allergy.13 Non-
pharmacological methods that address some of these can reduce
the use of H2RA and PPIs.14
Distinguishing physiological GOR and pathological GORD is
challenging. Symptoms related to GORD such as excessive crying,
regurgitation/vomiting, irritability and back arching frequently
occur in healthy infants, and there is also no evidence that these
symptoms are temporally associated with GOR events.15 Similarly
cardio-respiratory events often linked to GORD such as apnoea,
episodes of oxygen desaturation and swallowing dysfunction are
common in all preterm infants and studies show that suspected
clinical reflux behaviours do not correlate with acid reflux as
measured by oesophageal multichannel impedance.15
Interestingly, we found a higher prevalence of use of anti-reflux
medication compared to the prevalence of GORD diagnosis. This
suggests that anti-reflux medications are prescribed without the
diagnosis of GORD such as for a trial of a therapy which may be
used as a diagnostic tool. A survey of UK clinicians showed that
50% of the respondents regularly used clinical features plus
therapeutic trials to determine the diagnosis of GORD.10 Trials of
anti-reflux medications to establish a diagnosis of GORD are
recommended in older infants and children1 but such therapeutic
trials are not recommended in preterm infants because clinical
signs and symptoms do not correlate with acidic or non-acidic
reflux and the signs improve with time without treatment.7 Such
empirical treatments can alter the gut microbiome enhancing
pathogenic flora and increase the risks of NEC and infections.6
Shakeel et al.14 reported large reductions in the use of anti-reflux
medications with the implementation of guidelines that recom-
mended conservative and expectant management of GOR
symptoms until preterm infants were 37 weeks PMA, demonstrat-
ing that standardised clinical practice guidelines, with appropriate
education that addresses knowledge gaps in GORD management,
can reduce inappropriate use of anti-reflux medications.
Although Gaviscon, a preparation of sodium alginate combined
with sodium bicarbonate, was the most prescribed among the
total cohort (57% of all infants <32 weeks’ GA), H2RAs, mainly
ranitidine, use was more prevalent among the extremely preterm
infants, prescribed to 64%. In addition, 20% received PPIs. These
frequencies of use are higher, participially for H2RA use, than that
reported from 43 US hospitals between 2006 and 2013 where,
among infants <29 weeks’ GA, 24% had any H2RA and 17% had
any PPI.8
Not only did a larger proportion of extremely preterm infants
receive anti-reflux medications, they also received them for longer.
The median duration of anti-reflux prescription was 9 days longer
for those born at <28 weeks’ GA as compared to those born at
28–31 weeks’ GA. The US study recorded median (IQR) treatment
duration of 15 (6–35) days but this included preterm infants of
26–36 weeks GA.8 The longer use of medications among
extremely preterm infants could possibly be due to a more
prolonged course of GORD due to greater immaturity or because
they usually stayed longer in the neonatal unit which opens a
longer window of opportunity for medication use as compared to
those who were born at later gestations.
It was alarming to note the high use of prokinetics which was
prescribed to 45% of the cohort considering that the warning
issued by the Food and Drug Administration (FDA) in 2009 and by
the European Medicines Agency (EMA) in 20131 which clearly
stated that their potential side effects counterweigh the possible
benefits of these medications for the treatment of GORD in infants
<12 months of age.16 It was, therefore, reassuring that the use has
decreased significantly, particularly since 2013, perhaps in keeping
with the release of the EMA statement and, later, the UK Medicine
and Healthcare products Regulatory Authority (MHRA) announce-
ment on the risk of adverse cardiac events with domperidone.1
The use of H2RAs and Gaviscon also declined after 2013,
although not as rapidly. At this time, emerging evidence
suggested that the use of H2RA is associated with higher risks
of adverse effects including infections and NEC17,18, although this
was already mentioned in earlier guidelines.16 Gaviscon, perhaps
seen as more innocuous due to lack of evidence of such
associations also continues to be used frequently. It can decrease
the number of acidic GOR episodes, total oesophageal acid
exposure and the frequency of regurgitation events19,20 but there
is no evidence to show that it alleviates clinical signs and
symptoms.19,21
The use of PPIs has increased more than twofold during the
study period. A study conducted by Omari et al.22 showed that
omeprazole, a PPI, is effective in reducing the frequency of acid
reflux episodes and oesophageal acid exposure but has no impact
on clinical signs/symptoms in preterm infants. Moore et al.23
showed that omeprazole reduced the reflux index as compared to
placebo, but changes in clinical features were the same in both
groups. These findings are similar to studies using other PPIs such
as lansoprazole and esomeprazole.24,25
The use of the NNRD as source data has limitations as it is not
used for primary prescribing, and diagnoses are not recorded in a
standardised manner such as using ICD codes. There is a risk of
data entry errors and missing data. The lower prevalence in NNRD
data than the use of anti-reflux medications could also reflect
diagnoses not recorded or may represent the lack of formal
diagnosis. Additionally, due to the limited information included in
the database, we are unable to investigate the details of these
prescriptions including the dose and frequency of administration,
adverse events, response to medications, and why they were
stopped which are all vital information required to assess the
rational use of any medication. However, NNRD is the only large
database of neonatal data in the UK. The robustness and validity
of NNRD data have been previously demonstrated and it is
increasingly used for research.26 The use of this database allowed
us to analyse data from over 58,000 infants born at < 32 weeks’ GA
representing almost all the eligible population in England and
Wales from 2010 to 2017. To our knowledge, this is the first and
largest attempt in analysing the prevalence of GORD diagnosis
and the prescriptions of anti-reflux medications in England and
Wales with data from 200 neonatal units. The results provide
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valuable information on the use of anti-reflux medications in a
large population over a long period of time.
GORD remains an area fraught with diagnostic and manage-
ment conundrums27 and the high prevalence of use of medica-
tions despite the lack of evidence of benefit and associations with
potential harm, reflects these uncertainties. While large rando-
mised controlled trials are required to evaluate the benefits and
harms of using anti-reflux medications in preterm infants, such
studies cannot be performed without some clarity or consensus
on how to identify infants who have pathological GORD. When
perception of “troublesome” symptoms are used to diagnose and
treat GORD, trials show no evidence of benefit.28 Objective
determination of diagnosis such as using the acid reflux index27
can identify infants with true oesophageal acid exposure but do
not correlate with clinical signs and symptoms. Additionally, these
investigations are not used routinely in the UK10,11 and therefore
findings from studies using such methods of diagnosis may not
readily translate to change in practice. Pragmatic studies that
investigate methods of identifying infants thought to have
“troublesome” GORD, tool to monitor progression of signs and
symptoms attributed to GOR, and evaluation of practices that
could reduce the use of anti-reflux medications may help achieve
rational treatment for preterm infants.
CONCLUSION
Our findings suggest that anti-reflux medications are frequently
prescribed in very preterm infants despite evidence suggesting
that they are not effective and may be harmful. Further research
and clear guidelines for diagnosing GORD and for rationalising the
pharmacological management of GORD are required.
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